Fertility and Infertility Research News Portal » Fertility News

HCG diet Jersey Shore: JWoww Workout and Diet News Miami – Video

Sranjgospodnya — Wed, 08 Feb 2012 10:51:48 +0000

www.youtube.com/watch?v=2rE0W1vjGQQ

01-11-2011 13:57 www.hcgdropbydrop.com HCG diet news from our Miami office The MTV reality show Jersey Shore returns this week. This time the “guidos” and “guidettes” are hitting Miami Beach for more tanning, drinking, trouble-making, and working out. Indeed, JWoww (Jenny Farley) along with The Situation and DJ Pauly D are known for their smoking hot bodies. Between the shooting of the first season and the second season of Jersey Shore, JWoww told People that she did not work out at all and that she’d been able to stay in shape because of sleep deprivation and running around for all her publicity events. (We’re not so sure that sleep deprivation is a good way to stay in shape. Quite the contrary, to repair muscle or otherwise rest your body, you should be getting around 8 hours of sleep per night, though this number can vary from person to person.) However, it looks like JWoww has returned to the gym to work on that smoking body of hers. In particular, she’s been seen in Miami gyms (along with Snooki and Sammi) during the second season. Looks like her workout generally includes some boxing, jump roping, and treadmill running while shooting the second season. We’re assuming that this means that JWoww has given up on her unhealthy and unsustainable diet of 500 calories per day and fertility hormones. To put that in perspective, That’s Fit notes that an average-sized woman should be consuming about 1500 to 2000 calories per day (ie, 3-4 times as much. In addition, a 500-calorie diet can even …

Walgreens, CVS set to launch male fertility test that measures sperm count

indillNep — Wed, 08 Feb 2012 10:51:46 +0000

Walgreens and CVS, two of America's largest drugstore chains, are starting to sell a fertility test that will enable men to determine if they are producing enough sperm to get a woman pregnant.

Continue reading here:
Walgreens, CVS set to launch male fertility test that measures sperm count

illuminati fertility cult: MONEY SYSTEM is 5 LEVELS DEEP at least! – Video

Dnctva — Tue, 07 Feb 2012 12:10:42 +0000

www.youtube.com/watch?v=Z3RTku0uOW8

01-11-2011 21:12 www.ncbookz.com

Continued here:
illuminati fertility cult: MONEY SYSTEM is 5 LEVELS DEEP at least! – Video

11/15/11 Local News – Video

Mariano — Tue, 07 Feb 2012 12:10:41 +0000

www.youtube.com/watch?v=wv9NdOWkDYs

16-11-2011 14:54 Full Newscast:Mercy air lands on the roadway for a single vehicle rollover Pahrump Valley High School Band gets and excellent score at competition The 13th annual Pahrump Pow Wow is coming to town (Ax 160 Johnnie) One man was injured last night on north highway 160 in the town of Johnnie (PVHS band) Pahrump is proud of the performance that the Pahrump Valley High School Band (Soroptimist Electa Award) Electa Hewlett was only 53 years old when she succumbed to cancer November 6th of last year. She lived in Pahrump for 10 years. She was also an active member of the Soroptimist, as well as other numerous event committees in the community. She is also the daughter of Claudette B. Crooks who owns CC’S Beauty salon, and proudly was the mother of a special needs child. An award has been named after here. The first recipient received the Electa Hewlett award this weekend. (PVFR award) Firefighters from Pahrump Valley Fire and Rescue were honored with the Medal of Valor award for their efforts in fighting the fire at Amerigas propane in August. Fire Chief Scott Lewis gave five firefighter their metals at the Pahrump town board meeting. Congratulations and thank you to Pahrump Valley Fire and Rescue for clearly diverting a catastrophe (LV water park reader with photo) In a public/private partnership with Clark County, local investors and The Howard Hughes Corporation, it was announced today that a 25-acre, $18 million family waterpark will open Memorial Day Weekend near I-215 and …

View original post here:
11/15/11 Local News – Video

Genetic Armageddon Fed by the NWO – Video

interiordesign — Tue, 07 Feb 2012 12:10:40 +0000

www.youtube.com/watch?v=ZhaLP8ClANQ

06-01-2012 09:27 Infowars.com December 29, 2011 Food Is a Weapon, and Humanity is Under Siege by Globalists’ Chemical Cocktail. Proof that the government is poisoning the population. With their stated goal to reduce population worldwide, the eugenicists who run the world state have resorted to any means necessary to target reproduction and fertility, including the outrageous measures identified in the 1969 Planned Parenthood — World Population memo written by Frederick S. Jaffe. That memo proposes reducing US fertility via postponement of marriage, discouraging tax incentives for parents, encouraged increases in homosexuality, adding fertility control agents to the water supply and encouraging women to work, as well as measures including forced abortions and payments to encourage abortions. Many of these draconian calls for involuntary fertility control reflect some of the most controversial entries in the 1977 Ecoscience volume written by current White House science advisor John P. Holdren and population bomb scare-monger Paul Ehrlich. From Bisphenol-a (BPA), to GMO crops, fluoride in water and countless other toxins slow killing modern society, the elite controllers have intentionally triggered cancer, disease and sterility while trying to mask their attack through “slow” ambient poisons that gradually drag down the masses as they eat factory-produced foods, drink public water and are bombarded by toxic packaging products of all kinds. BPA and other synthetic estrogen-mimickers are …

Vitrolife AB (publ): Report on Operations 2011

GailiaTeS — Tue, 07 Feb 2012 12:10:39 +0000

GÖTEBORG, Sweden–(BUSINESS WIRE)–

Regulatory News:

Vitrolife AB (publ) (STO:VITR.ST – News):

Fourth quarter

— Sales increased by 19 percent in local currency. Sales were the highest ever for a single quarter and amounted to SEK 95 (81) million, corresponding to an increase of 18 percent in SEK.

— Operating income (EBIT) amounted to SEK 4 (9) million. The operating margin was 4 (11) percent. One-time expenses of SEK 7 million are included and consist of remuneration to the former CEO, write-down for a development project and disposal of production equipment. EBIT excluding one-time expenses amounted to SEK 11 million, corresponding to an operating margin of 11 percent.

— Income before tax amounted to SEK 4 (11) million. Net income amounted to SEK 2 (-1) million, which gave earnings per share of SEK 0.11 (-0.04).

— The cash flow from operating activities was SEK 10 (21) million.

— Magnus Nilsson handed over responsibility for the Group in order to be able to completely focus on Vitrolife’s transplantation area, Xvivo, which will be a more independent unit within Vitrolife. Thomas Axelsson was appointed Acting CEO.

Whole year

— Sales increased by 27 percent in local currency. Sales amounted to SEK 365 (298) million, corresponding to an increase of 20 percent in SEK.

— Operating income (EBIT) increased by 24 percent and amounted to SEK 41 (33) million. The operating margin was 11 (11) percent. One time expenses of SEK 7 million are included and consist of remuneration to the former CEO, write-down for a development project and disposal of production equipment. EBIT excluding one-time expenses amounted to SEK 48 million, corresponding to an operating margin of 13 percent.

— Income before tax increased by 9 percent to SEK 45 (41) million. Net income amounted to SEK 31 (29) million.

— Vitrolife was the first company to obtain regulatory approval in China for a whole series of cultivation media for IVF.

— A study showed that EmbryoGlue®, a product patented by Vitrolife, increases the chances of infertile women having children.

— A clinical study showing good results when using STEEN Solution™ was published in a prominent scientific journal. In all more than 100 patients have now received new lungs through the use of STEEN Solution™.

— Increased growth potential for Vitrolife in China – regulatory approval was obtained for instruments used in IVF treatment.

— Regulatory approval of aspiration needles in Japan, the second largest IVF market in the world.

— American study on STEEN Solution™ was begun and so far 7 out of a total number of 12 planned transplantations have been carried out.

After the end of the year

— The Board’s proposal for dividend amounts to SEK 0.60 (0.60) per share.

Gothenburg, February 7, 2012

VITROLIFE AB (publ)

The Board of Directors

Vitrolife is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on February 7, 2012 at 8:30 a.m.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

Vitrolife is a global biotechnology/medical device Group that works in the areas of Fertility and Transplantation. The Fertility product area works with nutrient solutions (media), cryopreservation products and advanced consumable instruments such as needles and pipettes, for the treatment of human infertility. Work is also carried out to enable the use and handling of stem cells for therapeutic purposes. The Transplantation product area works with solutions and systems for assessing and preserving organs outside the body, so as to be able to select usable organs and keep them in optimal condition pending transplantation.

Vitrolife today has approximately 220 employees and its products are sold in almost 90 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in USA, Australia, France, Italy, United Kingdom, China and Japan. The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452.

Tel: 46 31 721 80 00. Fax: 46 31 721 80 90. E-mail: info@vitrolife.com. Website: www.vitrolife.com/

This information was brought to you by Cision http://www.cisionwire.com

Read this article:
Vitrolife AB (publ): Report on Operations 2011

South Africa's white population may be extinct by 2161: Study

centerprestigezfv — Mon, 06 Feb 2012 17:25:40 +0000

Johannesburg, Feb 6 (ANI): South Africa's white and Indian population are declining, and the former figure may be extinct by the year 2161, a new study has revealed.

More:
South Africa's white population may be extinct by 2161: Study

Early Negative Pregnancy Test Before a Positive – Stats Study

admin — Mon, 06 Feb 2012 04:40:01 +0000

Early Negative Pregnancy Test Before a Positive – Stats StudySource:
http://www.fertilityfriend.com/ffrss/faqrss.xml

Slow Kill Holocaust – Proof the Government is Killing You .01 – Video

agcsyzmu — Fri, 03 Feb 2012 11:47:38 +0000

www.youtube.com/watch?v=kOHIVLxzdLQ

30-12-2011 21:35 NEWS Based on FACTS not PROPAGANDA. Playlist has all Videos for easier viewing. Proof that the government is poisoning the population. With their stated goal to reduce population worldwide, the eugenicists who run the world state have resorted to any means to target reproduction and fertility, including the outrageous measures identified in the 1969 Planned Parenthood — World Population memo written by Frederick S. Jaffe. That memo proposes reducing US fertility via postponement of marriage, discouraging tax incentives for parents, encouraged increases in homosexuality, adding fertility control agents to the water supply and encouraging women to work, as well as measures including forced abortion and payments to encourage abortions. Many of these draconian calls for involuntary fertility control reflect some of the most controversial entries in the 1977 Ecoscience volume written by current White House science advisor John P. Holdren and population bomb scare-monger Paul Ehrlich. From Bisphenol-a (BPA), to GMO crops, fluoride in water and countless other toxins slow killing modern society, the elite controllers have intentionally triggered cancer, disease and sterility while trying to mask their attack through “slow” ambient poisons that gradually drag down the masses as they eat factory-produced foods, drink public water and are bombarded by packaging products of all kinds. BPA and other synthetic estrogen-mimickers are particularly harmful, and widely used in food-grade …

Read this article:
Slow Kill Holocaust – Proof the Government is Killing You .01 – Video

New European pill works against uterine fibroids

primary-source — Fri, 03 Feb 2012 11:47:37 +0000

New research offers hope for the first pill to treat a common problem in young women: fibroids in the uterus. The growths can cause pain, heavy bleeding and fertility problems, and they are the leading cause of hysterectomies.

The rest is here:
New European pill works against uterine fibroids

Innovative Product Improves Chances of Conception

dentilfendjex — Wed, 01 Feb 2012 03:01:46 +0000

It may be surprising to know that 10% of Canadian couples have a difficult time conceiving. By age 30, experts say, a woman's chance of conceiving each month is about 20%, and by the time she reaches the age of 40, it drops to 5%. A new product, called Zestica Fertility, recently approved by Health Canada, is now available to help couples increase their chances of conceiving.Toronto, Ontario …

Originally posted here:
Innovative Product Improves Chances of Conception

Vitrolife AB (publ): Conference call Year-end report 2011

sxscraper — Tue, 31 Jan 2012 12:25:14 +0000

GÖTEBORG, Sweden–(BUSINESS WIRE)– Regulatory News:

Invitation to attend Vitrolife’s conference call regarding presentation of the Year-end report for 2011. The presentation will be held in English.

Time: Tuesday, February 7, 2012 at 10.00 a.m. CET.

Registration can preferably be done in advance under the following link: https://eventreg2.conferencing.com/webportal3/reg.html?Acc=526965&Conf=207356

or shortly before time of the conference starts on:

Sweden dial in number: +46 (0)8 505 201 14

UK dial in number: +44 (0)20 7162 0177

Conference name: Vitrolife, conference ID: 911127

Vitrolife participants:

Thomas Axelsson, acting CEO

Mikael Engblom, CFO

The press release for Vitrolife’s Year-end report will be released at 8.30 CET on the same day.

Before the conference call, slides will be available at the company web page, www.vitrolife.com/sv/Corporate/.

A recorded version of the presentation will be available for seven days on number +46 8 505 203 33 (Sweden) or 020 7031 4064 (UK), access code 911127.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

Vitrolife is a global biotechnology/medical device Group that has business activities within the areas of fertility and transplantation. The Fertility product area works with nutrient solutions (media), cryopreservation products and advanced consumable instruments such as needles and pipettes, for the treatment of human infertility. There is also business to enable the use and handling of stem cells for therapeutic purposes. The Transplantation product area works with solutions and systems to evaluate and maintain organs outside the body in order to select usable organs and keep them in optimal condition while waiting for transplantation.

Vitrolife today has approximately 220 employees and its products are sold in almost 90 markets. The company is headquartered in Gothenburg, Sweden, and there are offices in USA, Australia, France, Italy, United Kingdom, China and Japan. The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452.

Tel: 46 31 721 80 00. Fax: 46 31 721 80 90. E-mail: info@vitrolife.com. Website: www.vitrolife.com/

This information was brought to you by Cision http://www.cisionwire.com

Read the original here:
Vitrolife AB (publ): Conference call Year-end report 2011

New Lubricant Designed to Help Couples Get Pregnant

kZPcTrctMVpvnOT — Tue, 31 Jan 2012 12:25:13 +0000

For many couples, rather than being an enjoyable experience, trying to get pregnant can actually become a stressful and even a depressing experience. This is especially true when conception does not occur within the first year of trying. A new product, called Zestica Fertility, recently approved by Health Canada, is now available to help couples increase their chances of conceiving.Toronto …

Excerpt from:
New Lubricant Designed to Help Couples Get Pregnant

Testing the water before swimming: satisfying the need for clinical trials of devices, media, and instruments before their use in assisted reproduction laboratories

admin — Tue, 31 Jan 2012 04:58:22 +0000

The steady progress of assisted reproduction technologies (ART) realized significant improvements that increase the chance of delivering healthy offspring to parents suffering with infertility. Developments in ART laboratories, such as the introduction of new devices, instruments, and the evolution of culture media formulations, were crucial to this success. At present, laboratories and ART-related technology are light years from those that existed when the first test-tube babies were born.Source:
http://www.fertstert.org/current.rss

Contemporary aspects of male gamete (dys)function: aiming towards optimizing the treatment of fertilization disorders

admin — Tue, 31 Jan 2012 04:58:20 +0000

At its inception, in vitro fertilization (IVF) was a relatively straightforward procedure encompassing the in vitro insemination of surgically retrieved oocytes and the trans-cervical uterine placement of the ensuing embryos with the goal of overcoming tubal infertility. Since that time, IVF has become the ultimate treatment modality for all infertility indications when standard treatments have failed. While IVF has revolutionized our clinical armamentarium, it has also served as a remarkable scientific tool allowing direct visualization of male and female gamete interaction and assessment of human embryo development, thus enabling reproductive specialists to dissect and better understand the early human reproductive processes. In its earliest stages, IVF was directed at the treatment of female infertility focusing on the role of the oocyte, later to be eclipsed by assisted fertilization techniques that revolutionized the treatment of male factor infertility. The advent of assisted fertilization techniques, from the most simplistic approaches to direct sperm injection, has made it possible for suboptimal male gametes to penetrate the oocyte vestments. The latter technique has shed light on the ultimate function of the spermatozoon and the fascinating process of syngamy. Moreover, the ability to temporally monitor the cleaving embryo in vitro has enabled us to ascertain the individual steps involved in the development of the conceptus from syngamy to blastocyst as well as to shed light on hitherto unapproachable infertility etiologies.Source:
http://www.fertstert.org/current.rss

Development and current applications of assisted fertilization

admin — Tue, 31 Jan 2012 04:58:17 +0000

Since the very early establishment of in vitro insemination, it became clear that one of the limiting steps is the achievement of fertilization. Among the different assisted fertilization methods, intracytoplasmic sperm injection emerged as the ultimate technique to allow fertilization with ejaculated, epididymal, and testicular spermatozoa. This work describes the early steps that brought forth the development of intracytoplasmic sperm injection and its role in assisted reproductive techniques. The current methods to select the preferential male gamete will be elucidated and the concerns related to the offspring of severe male factor couples will be discussed.Source:
http://www.fertstert.org/current.rss

Semen analysis: looking for an upgrade in class

admin — Tue, 31 Jan 2012 04:58:13 +0000

Objective: To review the literature database regarding current methods for diagnosing male subfertility and to critique new testing methods that have the potential to be incorporated as part of routine semen analysis.Design: Literature database review.Setting: None.Patient(s): None.Intervention(s): None.Main Outcome Measure(s): None.Result(s): Methods for performing high quality semen analysis are standardized and clearly presented in the 2010 World Health Organization (WHO) laboratory manual for the examination and processing of human semen. In spite of the fact that lower reference limits contained therein are now evidence-based, debate persists about their clinical value. One test put forth as being additive to the semen analysis is assessment of DNA integrity. However, due to lack of standardized methods and quality control measures, accessibility to instrumentation, and evidence-based reference values for clinical interpretation this test has not become incorporated into the clinical andrology mainstream. Novel tests that probe molecular function have emerged that also have promise for integration into routine clinical semen analysis.Conclusion(s): Semen analysis, when performed according to WHO guidelines, will yield accurate and precise clinical laboratory data on traditional semen parameters. Due to the biological nature of the specimen in question definitive diagnosis of subfertility and its cause(s) remains enigmatic. Novel tests that may be easily standardized for subsequent multi-center, prospective randomized trials need to be integrated so more meaningful clinical diagnoses can be made.Source:
http://www.fertstert.org/current.rss

Epigenetics of the male gamete

admin — Tue, 31 Jan 2012 04:58:12 +0000

Objective: To review and summarize the current understanding of the epigenetic status of human sperm in regards to protamination, specific localization and modifications of retained histones, and DNA methylation.Design: Review of the relevant literature.Setting: University-based clinical and research laboratories.Patient(s): Fertile and infertile men.Intervention(s): None.Main Outcome Measure(s): Critical review of the literature.Result(s): Sperm from normospermic, fertile men have epigenetic modifications consistent with gene “poising” at the promoters of genes involved in development, including the localization of retained histones with bivalent histone modifications and hypomethylation of DNA. These epigenetic marks are altered in some patients with abnormal spermatogenesis, and in some men who exhibit unexplained, altered embryogenesis during IVF therapy.Conclusion(s): The sperm epigenome implies a poising of the paternal genome for embryogenesis and a possible role in the establishment of totipotency of the embryo and may help in understanding some causes of reduced fertility and transmission of disease risk.Source:
http://www.fertstert.org/current.rss

Human spermatozoal RNAs

admin — Tue, 31 Jan 2012 04:58:10 +0000

Objective: To provide a focused review of the scientific literature pertaining to spermatozoal RNA.Design: Review of the literature and appraisal of relevant articles.Setting: Not applicable.Patient(s): Infertile male.Intervention(s): None.Main Outcome Measure(s): Spermatozoal RNAs as potential epigenetic modifiers in early embryo development and as clinical markers of male infertility.Result(s): The nucleus of mature spermatozoa contains a complex population of mRNAs and miRNAs despite its transcriptionally inert state.Conclusion(s): A specific set of functional RNAs are delivered into oocytes during fertilization and are thought to contribute extragenomically to early embryonic development. Even if spermatozoal RNAs is merely residual, it still has the potential to greatly improve the investigative and diagnostic potential of male infertility.Source:
http://www.fertstert.org/current.rss

Increased maternal cardiovascular mortality associated with pregnancy in women with Turner syndrome

admin — Tue, 31 Jan 2012 04:58:07 +0000

In women with Turner syndrome, the risk of death from aortic dissection or rupture during pregnancy may be 2%, and this risk persists during the postpartum period owing to pregnancy-related aortic changes. Turner syndrome is a relative contraindication for pregnancy; however, it is an absolute contraindication for pregnancy in a patient with a documented cardiac anomaly. This document replaces the 2008 document of the same name.Source:
http://www.fertstert.org/current.rss

Genome-wide sperm deoxyribonucleic acid methylation is altered in some men with abnormal chromatin packaging or poor in vitro fertilization embryogenesis

admin — Tue, 31 Jan 2012 04:58:04 +0000

Objective: To evaluate genome-wide DNA methylation patterns in sperm from men with abnormal sperm chromatin packaging and patients displaying abnormal embryogenesis after IVF in the absence of known female factors.Design: Case–control study.Setting: University andrology and research laboratory.Patient(s): Men with abnormally high and low protamine 1/protamine 2 ratio (n = 15); patients who have undergone IVF/intracytoplasmic sperm injection resulting in abnormal embryogenesis (n = 13); and normozoospermic, fertile controls (n = 15).Intervention(s): Genome-wide sperm DNA methylation was measured using the Illumina Infinium HumanMethylation27 BeadChip assay. Follow-up targeted methylation analysis was performed using bisulfite pyrosequencing.Main Outcome Measure(s): Methylation levels at more than 27,000 CpGs genome-wide were compared between groups.Result(s): Of the 43 men analyzed, 40 displayed highly concordant methylation patterns; however, two men with abnormal protamine 1/protamine 2 and one abnormal embryogenesis patient displayed significantly altered methylation patterns across a large number of CpGs. Imprinted regions were more prone to deregulation than the genome at large.Conclusion(s): We have identified three individuals displaying broad disruption of sperm DNA methylation profiles. Although the sample set analyzed is relatively small, these results indicate that broad disruptions in sperm DNA methylation may be an important signature in some infertile men. Functional studies will be necessary to characterize the developmental consequences of such epigenetic disruption.Source:
http://www.fertstert.org/current.rss

Superoxide dismutase content in sperm correlates with motility recovery after thawing of cryopreserved human spermatozoa

admin — Tue, 31 Jan 2012 04:58:02 +0000

Objective: To investigate the correlation between sperm superoxide dismutase (SOD) content and motility recovery after thawing of cryopreserved human sperm, based on the rationale that this antioxidant enzyme provides protection against reactive oxygen species-induced damage during cryopreservation.Design: Prospective study.Setting: Private infertility institute and university-based research laboratory.Patient(s): Forty-two consenting normozoospermic patients consulting for infertility.Intervention(s): The SOD content was measured in sperm from unfractionated samples and in sperm recovered from the pellet fraction obtained after discontinuous density gradient centrifugation.Main Outcome Measure(s): Sperm motility was evaluated post-thaw in the two sets of samples and motility recovery was plotted against the sperm SOD content to determine their correlation.Result(s): There was a significant positive correlation between motility recovery after thawing and SOD content in sperm from the 90% gradient pellet containing highly purified mature sperm. There was also a significant negative correlation between motility after thawing and SOD content in the unfractionated sample.Conclusion(s): The positive correlation between post-thaw motility recovery and SOD content in mature spermatozoa provides a good predictor of post-thaw motility recovery after cryopreservation.Source:
http://www.fertstert.org/current.rss

The utility and cost of Chlamydia trachomatis and Neisseria gonorrhoeae screening of a male infertility population

admin — Tue, 31 Jan 2012 04:57:59 +0000

Objective: To determine the utility and cost of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) screening in infertile males.Design: Cohort study.Setting: Canadian tertiary-level male infertility clinic and university-affiliated laboratories.Patient(s): 5,588 male infertility patients.Intervention(s): CT and NG testing on 8,972 urine and semen samples.Main Outcome Measure(s): Prevalence of CT and NG infection in infertile males versus general male population in Canada over 8 years (2003–2010) and the reagent cost to detect one case of CT or NG.Result(s): In infertile males, the prevalence rate for CT and NG was 0.304% and 0.0537%, which was statistically significantly lower (3.4- and 8.1-fold lower, respectively) than the age-adjusted general population prevalence. With the reagents costing $86.20 per patient tested, the reagent cost alone to diagnose one case of CT or NG was $38,669.Conclusion(s): The prevalence of CT and NG in this study are among the lowest reported in the male infertility literature. These findings question the utility of CT/NG screening in this low-risk population and emphasize that decisions about the utility of screening must be based on the prevalence rates of the disease in the studied population.Source:
http://www.fertstert.org/current.rss

The management of retrograde ejaculation: a systematic review and update

admin — Tue, 31 Jan 2012 04:57:57 +0000

Objective: To determine the best management of retrograde ejaculation to optimize the chance of conception.Design: Systematic review.Setting: Tertiary reproductive medicine center.Patient(s): Subfertile men with retrograde ejaculation.Method(s): Systematic search of studies using search terms “management” or “therapy” or “treatment” and “retrograde ejaculation.” We excluded case reports and papers not in English.Main Outcome Measure(s): Pregnancy and live birth rates and rates of achievement of antegrade ejaculation.Result(s): Thirty-four studies met our criteria. Studies were mostly observational. Descriptions of predictive and confounding variables were often insufficient. The treatment options included urinary sperm retrieval and medical management with anticholinergics and sympathomimetics. Successful pregnancies and live births were also achieved using surgical techniques and electroejaculation; however, numbers were small.Conclusion(s): Many treatment options exist in the management of retrograde ejaculation; however, current literature is insufficient to allow firm comparisons between interventions. Treatment should be tailored, therefore, to the individual. Our findings support the need for further research in this area—including large randomized controlled trials. However, these would be difficult logistically and may not be possible.Source:
http://www.fertstert.org/current.rss

Normal live birth after testicular sperm extraction and intracytoplasmic sperm injection in variant primary ciliary dyskinesia with completely immotile sperm and structurally abnormal sperm tails

admin — Tue, 31 Jan 2012 04:57:55 +0000

Objective: To report on the investigation and fertility management of variant primary ciliary dyskinesia (PCD).Design: Case report.Setting: University-affiliated assisted reproductive technologies practice.Patient(s): A 40 year-old man presenting with 12 months’ primary infertility, complete sperm immotility, severe morphologic defects, and moderate sinopulmonary disease.Intervention(s): Electron microscopy (EM) of sperm, nasal cilial function studies, open testis biopsy, and sperm extraction for intracytoplasmic sperm injection (ICSI).Main Outcome Measure(s): Outcome of ICSI treatment using immotile testicular sperm.Result(s): EM revealed abnormal connecting pieces, shortened midpieces with attenuated mitochondrial sheaths, poorly developed annulus, abnormal outer dense fibers, and axonemes missing the two central mircotubules. Nasal ciliary beat frequency was subnormal and dyssynchronous. Immotile testicular sperm were selected for ICSI based on physical characteristics and fertilized 12 of 18 eggs. A single day-5 blastocyst achieved a normal pregnancy and delivery of a healthy 3,840-g girl at 38 weeks’ gestation.Conclusion(s): Nonclassic PCD may present with structurally abnormal completely immotile sperm, with seemingly little prospect of fertility, and moderate respiratory dysfunction supporting the presence of an underlying ciliopathy. Despite testicular sperm also being immotile and showing profound structural defects that would seem to preclude fertilization, more morphologically normal sperm are capable of establishing a normal pregnancy.Source:
http://www.fertstert.org/current.rss